Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk

Current Medical Research and Opinion

Volumn 31, Issue 3, 2015, Pages 557-574

  Lebrec, Hervé ^a   Ponce, Rafael ^a   Preston, Bradley D ^a   Iles, Jan ^a   Born, Teresa L ^a   Hooper, Michele ^a  

^a AMGEN INC   (United States)

Author keywords

Cancer; Inflammation; Malignancy; TNF; TNF inhibition; Tumor

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANGIOGENESIS; AUTOIMMUNITY; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); GENETIC POLYMORPHISM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSURVEILLANCE; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN CANCER; SOLID TUMOR; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; VIRUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASM; RISK FACTOR; TUMOR RECURRENCE;

ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTORS;

EID: 84924546780     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1011778     Document Type: Review

References (184)

1. Ponce RA, Gelzleichter T, Haggerty HG, et al. Immunomodulation and lymph-oma in humans. J Immunotoxicol 2014;11:1-12
2. Yaqub S, Aandahl EM. Inflammation versus adaptive immunity in cancer pathogenesis. Crit Rev Oncog 2009;15:43-63
3. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-17
4. Borrello MG, Degl'Innocenti D, Pierotti MA. Inflammation and cancer: the oncogene-driven connection. Cancer Lett 2008;267:262-70
5. Kraus S, Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol 2009;9:405-10
6. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr 1995;126:1-10
7. Filipovich AH, Mathur A, Kamat D, et al. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency 1994;5:91-112
8. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-62
9. Reed M, Cosgrove JM, Cindrich R, et al. Ten years later: a single hospital experience with malignancy in HIV/AIDS. J Surg Oncol 2010;102:282-6
10. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187-94
11. Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immuno-suppressive regimens after kidney transplantation. J Am Soc Nephrol 2010;21:852-8
12. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009;125:1747-54
13. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67
14. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13
15. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9
16. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
17. Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38:904-10
18. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12: 298-306
19. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4
20. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immuno-surveillance to tumor escape. Nat Immunol 2002;3:991-8
21. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71
22. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001;13:458-64
23. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004;24:439-54
24. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37
25. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007;19:209-16
26. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44
27. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-81
28. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117: 244-79
29. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70
30. Green S, Dobrjansky A, Carswell EA, et al. Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1976;73:381-5
31. Shirai T, Yamaguchi H, Ito H, et al. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 1985;313:803-6
32. Wang AM, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985;228:149-54
33. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7
34. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170:1627-33
35. Aggarwal BB, Henzel WJ, Moffat B, et al. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem 1985;260:2334-44
36. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984;259:686-91
37. Gray PW, Aggarwal BB, Benton CV, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984;312:721-4
38. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985;260: 2345-54
39. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984;312:724-9
40. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991;266:7313-16
41. Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80
42. Simponi (golimumab). Full Prescribing Information. Horsham, PA, USA: Janssen Biotech Inc., 2014
43. Remicade (infliximab). Full Prescribing Information. Horsham, PA, USA: Janssen Biotech, Inc., 2013
44. Humira (adalimumab). Full Prescribing Information. North Chicago, IL, USA: Abbott Laboratories, 2013
45. Cimzia (certolizumab pegol). Full Prescribing Information. Smyrna, GA, USA: UCB Inc., 2013
46. Enbrel (etanercept). Full Prescribing Information. Thousand Oaks, CA, USA: Immunex Corporation, 2013
47. Data on File. Thousand Oaks, CA, USA: Amgen Inc., 2014
48. Brouckaert PG, Leroux-Roels GG, Guisez Y, et al. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 1986;38:763-9
49. Balkwill FR, Lee A, Aldam G, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with inter-ferons. Cancer Res 1986;46:3990-3
50. Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol 2013;230:241-8
51. Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb per-fusion for melanoma patients-A review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol 2006;32:371-80
52. Grunhagen DJ, de Wilt JH, van Geel AN, et al. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res 2009;179:257-70
53. Deroose JP, Eggermont AM, van Geel AN, et al. Long-term results of tumor necrosis factor alpha-and melphalan-based isolated limb perfu-sion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011;29:4036-44
54. Di Filippo F, Giacomini P, Rossi CR, et al. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo 2009;23:363-7
55. Alexander Jr HR, Bartlett DL, Libutti SK, et al. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 2009;16:1852-9
56. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408-14
57. Zhang F, Decker K. Platelet-activating factor antagonists suppress the generation of tumor necrosis factor-alpha and superoxide induced by lipopolysaccharide or phorbol ester in rat liver macrophages. Eur Cytokine Netw 1994;5:311-17
58. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71
59. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90
60. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;274:782-4
61. Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305
62. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996;274:787-9
63. Pan S, An P, Zhang R, et al. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol 2002;22:7512-23
64. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? 1. Acta Pharmacol Sin 2008;29:1275-88
65. Balkwill F. TNF-A in promotion and progression of cancer. Cancer Metastasis Rev 2006;25:409-16
66. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99
67. Ren G, Zhao X, Wang Y, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFa. Cell Stem Cell 2012;11:812-24
68. Perkins ND. The diverse and complex roles of NF-kB subunits in cancer. Nature Reviews Cancer 2012;12:121-32
69. Volk A, Li J, Xin J, et al. Co-inhibition of NF-kB and JNK is synergistic in TNF-expressing human AML. J Exp Med 2014;211:1093-108
70. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012;246:379-400
71. Suganuma M, Okabe S, Marino MW, et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999;59:4516-18
72. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5:828-31
73. Bernert H, Sekikawa K, Radcliffe RA, et al. Trifa and I1-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog 2003;38:117-23
74. Starcher B. Role for tumour necrosis factor-alpha receptors in ultraviolet-induced skin tumours. Br J Dermatol 2000;142:1140-7
75. Karabela SP, Kairi CA, Magkouta S, et al. Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice. Neoplasia 2011;13:1143-51
76. Knight B, Yeoh GC, Husk KL, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000;192:1809-18
77. Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008;68:1443-50
78. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008;118:560-70
79. Devoogdt N, Revets H, Kindt A, et al. The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor. J Immunol 2006;177:8046-52
80. Stolting MN, Ferrari S, Handschin C, et al. Myoblasts inhibit prostate cancer growth by paracrine secretion of tumor necrosis factor-alpha. J Urol 2013;189:1952-9
81. Ouyang W, Hu Y, Li J, et al. Direct evidence for the critical role of NFAT3 in benzo[a]pyrene diol-epoxide-induced cell transformation through mediation of inflammatory cytokine TNF induction in mouse epidermal Cl41 cells. Carcinogenesis 2007;28:2218-26
82. Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithe-lial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003;14:1790-800
83. Fleischman AG, Aichberger KJ, Luty SB, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011;118:6392-8
84. Choo MK, Sakurai H, Koizumi K, Saiki I. Stimulation of cultured colon 26 cells with TNF-alpha promotes lung metastasis through the extracellular signal-regulated kinase pathway. Cancer Lett 2005;230:47-56
85. Shin SY, Kim JH, Baker A, et al. Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor alpha. Mol Cancer Res 2010;8:507-19
86. Malik ST, Naylor MS, East N, et al. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990;26:1031-4
87. Orosz P, Kruger A, Hubbe M, et al. Promotion of experimental liver metastasis by tumor necrosis factor. Int J Cancer 1995;60:867-71
88. Cubillos S, Scallon B, Feldmann M, Taylor P. Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model. Anticancer Res 1997;17:2207-11
89. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immuno-suppressive networks during malignant progression. Cancer Res 2006;66:5527-36
90. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011;60:1161-71
91. Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur J Immunol 2000;30:1957-66
92. Iizuka K, Chaplin DD, Wang Y, et al. Requirement for membrane lymphotoxin in natural killer cell development. Proc Natl Acad Sci USA 1999;96:6336-40
93. Xu J, Chakrabarti AK, Tan JL, et al. Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk. Blood 2007;109:3333-41
94. Eugster HP, Muller M, Karrer U, et al. Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice. Int Immunol 1996;8:23-36
95. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-8
96. De Togni P, Goellner J, Ruddle NH, et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994;264:703-7
97. Kim EY, Teh SJ, Yang J, et al. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth. J Immunol 2009;183:6051-7
98. Kondo A, Yamashita T, Tamura H, et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 2010;116:1124-31
99. Zhao X, Rong L, Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012;122:4094-104
100. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000;164:3645-51
101. Swann JB, Vesely MD, Silva A, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008;105:652-6
102. Kammertoens T, Qin Z, Briesemeister D, et al. B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-alpha, perforin). Int J Cancer 2012;131:1499-508
103. Tanigawa K, Craig RA, Stoolman LM, Chang AE. Effects of tumor necrosis factor-alpha on the in vitro maturation of tumor-reactive effector T cells. J Immunother 2000;23:528-35
104. Ito D, Back TC, Shakhov AN, et al. Mice with a targeted mutation in lym-photoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment. J Immunol 1999;163:2809-15
105. Korner H, Cook M, Riminton DS, et al. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur J Immunol 1997;27:2600-9
106. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-52
107. Grimm M, Lazariotou M, Kircher S, et al. Tumor necrosis factor-alpha is associated with positive lymph node status in patients with recurrence of colorectal cancer-indications for anti-TNF-alpha agents in cancer treatment. Anal Cell Pathol (Amst) 2010;33:151-63
108. Vohra N, Verhaegen M, Martin L, et al. TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model. Cancer Immunol Immunother 2010;59:729-36
109. Kim DH, Kim EM, Lee EH, et al. Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells. Biochem Biophys Res Commun 2011;409:792-8
110. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7
111. Miceli-Richard C, Gestermann N, Amiel C, et al. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther 2009;11:R77
112. Balandraud N, Guis S, Meynard JB, et al. Long-term treatment with metho-trexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:762-7
113. Couderc M, Payet S, Henquell C, et al. TNFalpha antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis. Joint Bone Spine 2010;77:414-17
114. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
115. Maccio A, Madeddu C. Inflammation and ovarian cancer. Cytokine 2012;58:133-47
116. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010;102:639-44
117. Bauer J, Namineni S, Reisinger F, et al. Lymphotoxin, NF-kB, and cancer: the dark side of cytokines. Dig Dis 2012;30:453-68
118. Kroeger KM, Carville KS, Abraham LJ. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997;34:391-9
119. Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6
120. Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer 2008;98:1443-51
121. Jin G, Zhao Y, Sun S, Kang H. Association between the tumor necrosis factor alpha gene-308G4A polymorphism and the risk of breast cancer: a meta-analysis. Tumour Biol 2014;35:12091-8
122. Min L, Chen D, Qu L, Shou C. Tumor necrosis factor-A polymorphisms and colorectal cancer risk: a meta-analysis. PLoS One 2014;9:e85187
123. Rokkas T, Sechopoulos P, Pistiolas D, et al. Population differences concerning TNF-alpha gene polymorphisms in gastric carcinogenesis based on meta-analysis. Ann Gastroenterol 2014;27:139-48
124. Shen C, Sun H, Sun D, et al. Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011;126:763-70
125. Wang J, Jin X, Wang H, et al. The-308G/A polymorphism of the tumor necrosis factor-alpha gene is associated with the risk of upper aerodigestive tract cancer: a meta-analysis. Tohoku J Exp Med 2013;229:245-54
126. Xie H, Yao H, Huo Y, et al. Association between TNF-alpha gene 308G4A polymorphism and lung cancer risk: a meta-analysis. Tumour Biol 2014;35:9693-9
127. Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011;137:947-52
128. Zhai K, Ding J, Zhou Y. Different role of tumor necrosis factor-alpha polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysis. Int J Mol Sci 2014;15:7684-98
129. Zhang HL, Zhang YJ. A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer. Tumour Biol 2013;34:1659-65
130. Feng RN, Liu GY, Wang C, et al. TNF polymorphisms and cancer. Asian Pac J Cancer Prev 2012;13:3007
131. Cen G, Wu W. Association between tumor necrosis factor-alpha 857C/T polymorphism and gastric cancer: a meta-analysis. Tumour Biol 2013;34:3383-8
132. Tsukasaki K, Miller CW, Kubota T, et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001;61:3770-4
133. Menke V, van Zoest KP, Moons LM, et al. NcoI TNF-beta gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. Scand J Gastroenterol 2012;47:378-86
134. Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990;76:393-400
135. Barak V, Nisman B, Polliack A. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 1999;62:71-5
136. Freedman MH, Cohen A, Grunberger T, et al. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol 1992;80:40-8
137. Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011-23
138. Senthilkumar C, Niranjali S, Jayanthi V, et al. Molecular and histo-logical evaluation of tumor necrosis factor-alpha expression in Helicobacter pylori-mediated gastric carcinogenesis. J Cancer Res Clin Oncol 2011;137:577-83
139. Suganuma M, Kuzuhara T, Yamaguchi K, Fujiki H. Carcinogenic role of tumor necrosis factor-alpha inducing protein of Helicobacter pylori in human stomach. J Biochem Mol Biol 2006;39:1-8
140. Dreyer L, Mellemkjaer L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides-A follow-up study from the DANBIO Registry. Ann Rheum Dis 2013;72:79-82
141. Mercer LK, Davies R, Galloway JB, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 2013;52:91-8
142. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701
143. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95
144. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20
145. Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology 2008;47:698-701
146. Ramadan SM, Fouad TM, Summa V, et al. Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 2012;97:805-17
147. Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011;41:71-80
148. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2014; [Epub]. doi 10.1136/annrheumdis-2013-204851. March 31, 2014
149. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996;14:551-3
150. Symmons DP, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis. Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997;40:1955-61
151. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74
152. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5
153. Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of TNF inhibitors in rheumatoid arthritis-A meta-analysis update of 44 randomized controlled trials. Am J Med 2014;127:1208-32
154. Wu C-Y, Chen D-Y, Shen J-L, et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther 2014;16:449
155. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30
156. Gottlieb AB, Gordon K, Giannini EH, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011;10:289-300
157. Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48-58
158. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904
159. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24
160. Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014;43:489-97
161. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6
162. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703
163. Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010;9:175-80
164. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5
165. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64
166. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53
167. Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etaner-cept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:373-82
168. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45
169. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908
170. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-a) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;108:99-105
171. Mariette X, Reynolds AV, Emery P. Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. Ann Rheum Dis 2012;71:e2
172. Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013;346:f1939
173. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35
174. Ali T, Kaitha S, Mahmood S, et al. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 2013;5:79-99
175. National Cancer Institute. HPV and cancer: fact sheet. 2014. Available at: http://www.cancer.gov/cancertopics/factsheet/Risk/HPV/print [Last accessed 6 June 2014]
176. Mercer LK, Low ASL, Galloway JB, et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis 2013;72:143-4
177. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
178. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010;49:2217-19
179. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39
180. Dixon W, Watson K, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010;62:755-63
181. Raaschou P, Frisell T, Askling J, et al. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014; [Epub]. doi:10.1136/annrheumdis-2014-205745. August 8, 2014
182. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141
183. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64:1263-71
184. Peyrin-Biroulet L, Deltenre P, De Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53